Protonix Settlement Leaves Question Of How Jury Would Assess At-Risk Launch Damages

Teva and Sun are to pay $2.15 billion for their at-risk launch of generic versions of Pfizer’s Protonix; Pfizer says figure represents lost profits and lost royalties from the three years the product faced premature generic competition.